MARKET

TRVI

TRVI

Trevi Therapeutics
NASDAQ
2.520
-0.130
-4.91%
Closed 16:00 02/08 EST
OPEN
2.590
PREV CLOSE
2.650
HIGH
2.670
LOW
2.347
VOLUME
50.60K
TURNOVER
43.21K
52 WEEK HIGH
4.683
52 WEEK LOW
0.4600
MARKET CAP
151.01M
P/E (TTM)
-2.9900
1D
5D
1M
3M
1Y
5Y
BRIEF-Trevi Therapeutics Provides Business Update Ahead Of Upcoming Conferences
Reuters · 01/05 21:08
Organigram And Rounding Out My Tax Loss Selling Basket
Seeking Alpha · 01/02 12:07
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2022 Update
Seekingalpha · 12/26/2022 07:27
Why Manchester United Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Benzinga · 11/23/2022 12:38
SVB Leerink Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $6
Benzinga · 11/22/2022 11:14
--SVB Securities Starts Trevi Therapeutics at Outperform With $6 Price Target
--SVB Securities Starts Trevi Therapeutics at Outperform With $6 Price Target
MT Newswires · 11/22/2022 08:12
--Oppenheimer Adjusts Trevi Therapeutics Price Target to $9 From $12 Mainly on Higher Discount Rate, Maintains Outperform Rating
--Oppenheimer Adjusts Trevi Therapeutics Price Target to $9 From $12 Mainly on Higher Discount Rate, Maintains Outperform Rating
MT Newswires · 11/15/2022 11:00
--Needham Trims Price Target on Trevi Therapeutics to $8 From $10, Maintains Buy Rating
--Needham Trims Price Target on Trevi Therapeutics to $8 From $10, Maintains Buy Rating
MT Newswires · 11/11/2022 11:03
More
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (nalbuphine ER) to treat neurologically mediated conditions. It is engaged in developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Haduvio is an oral extended-release (ER) formulation of nalbuphine. It is conducting Phase IIb/3 clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It is also conducting Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as Phase II CANAL trial. It has also commenced Phase Ib trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics of Haduvio. Its Haduvio development programs include Active Chronic Pruritus Programs, Prurigo Nodularis Program, and Chronic Cough in Idiopathic Pulmonary Fibrosis Program.

Webull offers kinds of Trevi Therapeutics Inc stock information, including NASDAQ:TRVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TRVI stock methods without spending real money on the virtual paper trading platform.